Impurity issue stops Aurobindo irbesartan
Executive Summary
A certificate of suitability (CEP) issued for bulk irbesartan made by Aurobindo Pharma in Hyderabad, India, has been suspended by the European Directorate for the Quality of Medicines (EDQM). Several other CEPs for irbesartan from other active pharmaceutical ingredient (API) suppliers remain in force.
You may also be interested in...
Nitrosamine Testing Policy From European Pharmacopeia’ Largely Aligns With USP
Two groups have issued largely complementary testing methods for measuring nitrosamine impurities in drugs, and the differences that do exist are “insignificant,” EDQM official advises. The two are working to further harmonize testing standards, given the global scope of the nitrosamine scare.
Stock Watch: Reinforcements Required As Darzalex Carries J&J
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.